AUS
NZ
UK
CA
USA
IND
Highlights:
- Optiscan (ASX:OIL) initiates a pre-clinical study with the University Medical Center of Johannes Gutenberg University Mainz, utilizing its Gen2 technology for real-time GI tract imaging.
- The major aim is to improve diagnosis and treatment of GI diseases, such as cancer, by providing high-resolution, real-time visualizations that could reduce the need for multiple biopsies.
- The study marks a significant step toward developing the Gen3 flexible endomicroscope and enhancing AI algorithm development in collaboration with Monash University.
Optiscan Imaging Limited (ASX:OIL) embarks on a crucial pre-clinical gastrointestinal (GI) study aimed at revolutionizing diagnostics and treatment methodologies. This study is being conducted in partnership with the University Medical Center of Johannes Gutenberg University Mainz in Germany. The initiative is a significant advancement in Optiscan's mission to utilize cutting-edge technology for real-time imaging of the GI tract.
The latest initiative employs Optiscan's Gen2 imaging technology, which seeks to transform the landscape of GI diagnostics. By capturing high-resolution, real-time images of cellular structures, the technology aims to enhance the early detection and diagnosis of GI diseases, particularly cancer. This capability promises to facilitate the identification of abnormalities such as pre-cancerous lesions, potentially reducing the necessity for multiple biopsies.
A critical component of the project involves the collaboration with Monash University, focusing on the development of Edge-AI-enabled technology. This partnership is anticipated to enhance the creation of AI algorithms that will further bolster Optiscan’s capabilities in delivering precise diagnostics. As part of these endeavors, the staged development approach will guide the transition from pre-clinical to clinical phases, ultimately leading to the introduction of a more advanced, Gen3 flexible endomicroscope for optimal clinical application.
The global health implications of this study are paramount, addressing the pressing need for innovative solutions to combat the rising tide of GI disorders. With colorectal cancer documented as a leading cause of cancer-related deaths globally, Optiscan's efforts could provide pivotal contributions to more effective clinical interventions. Traditional diagnostic techniques have been hampered by invasive processes and delays in obtaining results, thus underscoring the value of real-time solutions.
Under the guidance of internationally respected gastroenterologist Professor Ralf Kiesslich, this study represents a pivotal step forward in expanding the efficacy of Optiscan's high-resolution imaging technology. The initiative marks a concerted effort by the company to re-establish its presence in the competitive GI endoscopy market, deploying its privately branded devices in collaboration with industry leaders.
CEO Dr. Camile Farah highlighted the importance of this study in overcoming global health challenges presented by GI diseases. With the tangible potential to make real-time imaging a standard practice, Optiscan is set to enhance patient outcomes by streamlining procedural efficiency and improving decision-making processes.
As the study progresses, Optiscan is also working towards securing ethical clearance for forthcoming clinical trials. This aligns with its strategic objectives of setting industry benchmarks in diagnostic technology, thereby contributing to the evolution of global healthcare solutions.
